Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Zelija Velija, Asimi"'
Autor:
Saif Alnuaimi, Tea Reljic, Fatima S. Abdulla, Hamda Memon, Sarah Al-Ali, Teagen Smith, Fadila Serdarevic, Zelija Velija Asimi, Ambuj Kumar, Sabina Semiz
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract The combination of metformin and the peroxisome proliferator-activated receptors (PPAR) agonists offers a promising avenue for managing type 2 diabetes (T2D) through their potential complementary mechanisms of action. The results from random
Externí odkaz:
https://doaj.org/article/1fdd5ee105ac470ab794c28e43dbd363
Publikováno v:
Genetics & Applications, Vol 2, Iss 2, Pp 73-77 (2018)
MODY (maturity-onset diabetes of the young) is an autosomal dominant form of diabetes that is usually manifested before the 25-year of life. This type of diabetes is caused by defects in the primary insulin secretion. There are several types of MODY,
Externí odkaz:
https://doaj.org/article/ebb69bd9e8724fa4a50e82c55afaaaeb
Autor:
Tanja Dujic, Tamer Bego, Maja Malenica, Zelija Velija-Asimi, Emma Ahlqvist, Leif Groop, Ewan R. Pearson, Adlija Causevic, Sabina Semiz
Publikováno v:
Biomolecules & Biomedicine, Vol 19, Iss 4 (2019)
The response to metformin, the most commonly used drug for the treatment of type 2 diabetes (T2D), is highly variable. The common variant rs7903146 C>T within the transcription factor 7-like 2 gene (TCF7L2) is the strongest genetic risk factor associ
Externí odkaz:
https://doaj.org/article/f4eeead7bc3e4f349eb99895e8c00ad5
Autor:
Tatjana Milenkovic, Nadica Bozhinovska, Djuro Macut, Jelica Bjekic-Macut, Dario Rahelic, Zelija Velija Asimi, Azra Burekovic
Publikováno v:
Nutrients, Vol 13, Iss 4, p 1307 (2021)
For the past 80 years, the effect of the Mediterranean diet on overall health has been a constant topic of interest among medical and scientific researchers. Parallel with the persistent global rise of cases of type 2 diabetes, many studies conducted
Externí odkaz:
https://doaj.org/article/947c58aeb2fe465f98a23abff476260d
Autor:
Jelica Bjekic-Macut, Tatjana Madić, Zoran Andrić, Sarantis Livadas, Zelija Velija-Asimi, Slobodanka Crevar-Marinović, Marija Branković, Azra Burekovic, Danijela Vojnović Milutinović, Olivera Stanojlović, George Mastorakos, Marija Zdravkovic, Tamara Vukasin
Publikováno v:
Current Pharmaceutical Design. 27:3812-3820
Polycystic ovary syndrome (PCOS) is a frequent endocrine disease in women during the reproductive period. It is considered a complex metabolic disorder with long-term metabolic, as well as reproductive consequences. Main pathophysiological pathways a
Autor:
Nadica Bozhinovska, Azra Burekovic, Dario Rahelić, Tatjana Milenkovic, Djuro Macut, Zelija Velija Asimi, Jelica Bjekic-Macut
Publikováno v:
Nutrients, Vol 13, Iss 1307, p 1307 (2021)
Nutrients
Nutrients
For the past 80 years, the effect of the Mediterranean diet on overall health has been a constant topic of interest among medical and scientific researchers. Parallel with the persistent global rise of cases of type 2 diabetes, many studies conducted
Autor:
Adlija Causevic, Sabina Semiz, Janja Marc, Zelija Velija-Asimi, Tamer Bego, Besim Prnjavorac, Tanja Dujic, Vladimir Palicka, Jana Nekvindová, Maja Malenica
Publikováno v:
Journal of Medical Biochemistry, Vol 38, Iss 2, Pp 153-163 (2019)
Journal of Medical Biochemistry
Journal of Medical Biochemistry
Summary Background FTO, a gene recently discovered in genomewide associated studies for type 2 diabetes mellitus (T2D), play an important role in the management of energy homeostasis, nucleic acid demethylation and regulation of body fat mass by lipo
Publikováno v:
Genetics & Applications, Vol 2, Iss 2, Pp 73-77 (2018)
MODY (maturity-onset diabetes of the young) is an autosomal dominant form of diabetes that is usually manifested before the 25-year of life. This type of diabetes is caused by defects in the primary insulin secretion. There are several types of MODY,
Autor:
Vanja Karlovic, Beslic, Azra, Burekovic, Zahida, Drace, Zelija, Velija-Asimi, Amela, Dizdarevic-Bostandzic
Publikováno v:
Materia Socio Medica. 34:92
Background: Polyglandular autoimmune syndrome type III (PAS III) is combination two most common autoimmune disease: Diabetes mellytus type 1 (DM1) and autoimmune thyroid disease (AITD). Objectives: The aims of the study were a) to define conection be
Autor:
Amela Dizdarevic, Bostandzic, Vanja Karlovic, Beslic, Ismana, Surkovic, Sefkija, Balic, Tanja, Dujic, Zelija Velija, Asimi, Azra, Burekovic
Publikováno v:
Medical Archives. 76:96
IDegLira( fixed combination of GLP 1 receptor agonist and insulin) has been shown to be effective in improving the glucoregulation in patients previously treated with oral therapy as well as individual components, GLP-1 receptor agonist or basal insu